Your browser is no longer supported. Please, upgrade your browser.
SCMP Sucampo Pharmaceuticals, Inc. daily Stock Chart
Sucampo Pharmaceuticals, Inc.
Index- P/E26.16 EPS (ttm)0.41 Insider Own0.10% Shs Outstand46.45M Perf Week-1.38%
Market Cap499.34M Forward P/E7.32 EPS next Y1.47 Insider Trans-88.89% Shs Float29.77M Perf Month-11.52%
Income18.50M PEG1.87 EPS next Q0.30 Inst Own55.10% Short Float24.28% Perf Quarter-19.05%
Sales230.10M P/S2.17 EPS this Y-42.20% Inst Trans33.48% Short Ratio6.87 Perf Half Y-16.92%
Book/sh3.88 P/B2.77 EPS next Y4.11% ROA3.90% Target Price17.43 Perf Year6.02%
Cash/sh- P/C- EPS next 5Y14.00% ROE13.80% 52W Range9.62 - 17.55 Perf YTD-20.66%
Dividend- P/FCF70.33 EPS past 5Y24.80% ROI9.60% 52W High-38.86% Beta1.39
Dividend %- Quick Ratio8.80 Sales past 5Y33.30% Gross Margin67.00% 52W Low11.54% ATR0.54
Employees139 Current Ratio9.50 Sales Q/Q31.80% Oper. Margin17.30% RSI (14)45.35 Volatility3.90% 4.85%
OptionableYes Debt/Eq1.74 EPS Q/Q50.30% Profit Margin8.00% Rel Volume0.16 Prev Close10.75
ShortableYes LT Debt/Eq1.74 EarningsMar 08 BMO Payout0.00% Avg Volume1.05M Price10.73
Recom2.30 SMA20-4.22% SMA50-6.23% SMA200-13.25% Volume12,739 Change-0.19%
Mar-10-17Reiterated WallachBeth Buy $20 → $15
Mar-09-17Reiterated Mizuho Buy $16 → $14
Mar-06-17Reiterated Mizuho Buy $16
Dec-22-16Upgrade Mizuho Neutral → Buy $16
Nov-15-16Reiterated Maxim Group Buy $17 → $19
Nov-14-16Reiterated Mizuho Neutral $13 → $16
Sep-07-16Initiated Northland Capital Outperform
Aug-04-16Downgrade Mizuho Buy → Neutral $13
Aug-01-16Reiterated Maxim Group Buy $26 → $17
May-05-16Upgrade WallachBeth Hold → Buy $16
Apr-20-16Upgrade Mizuho Neutral → Buy $14
Mar-10-16Reiterated WallachBeth Hold $27 → $16
Mar-09-16Reiterated Maxim Group Buy $25 → $26
Jan-15-16Reiterated Mizuho Neutral $19 → $14
Nov-20-15Initiated Jefferies Hold $19
Nov-13-15Reiterated Mizuho Neutral $22 → $19
Oct-29-15Resumed ROTH Capital Buy $29
Oct-09-15Initiated Mizuho Neutral
Sep-03-15Initiated Leerink Partners Mkt Perform
Aug-27-15Reiterated WallachBeth Hold $24 → $27
Mar-16-17 05:50PM  Local drug company stocks react to Trump's proposed cuts to NIH, FDA at
Mar-15-17 05:01PM  Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the Oppenheimer 27th Annual Healthcare Conference GlobeNewswire
Mar-14-17 01:04PM  SUCAMPO PHARMACEUTICALS, INC. Financials
10:11AM  Sucampo Pharmaceuticals (SCMP): Moving Average Crossover Alert
Mar-13-17 08:54AM  SUCAMPO PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Mar-09-17 10:54AM  Sucampo Pharmaceuticals, Inc. :SCMP-US: Earnings Analysis: Q4, 2016 By the Numbers : March 9, 2017 -6.64%
10:53AM  Sucampo (SCMP) Beats Q4 Earnings, 2017 View Reaffirmed
Mar-08-17 10:20PM  Edited Transcript of SCMP earnings conference call or presentation 8-Mar-17 1:30pm GMT +7.11%
01:21PM  Here's Why Sucampo Pharmaceuticals Rose as Much as 13.3% Today at Motley Fool
10:08AM  Nasdaq Leads On Chips; Dow Dips As Caterpillar Off, Banks Up
09:11AM  Biotech Premarket Movers: Sucampo, Intellia, Cytokinetics
08:30AM  Sucampo Pharmaceuticals Inc Earnings Call scheduled for 8:30 am ET today
07:07AM  Q4 2016 Sucampo Pharmaceuticals Inc Earnings Release - Before Market Open
06:48AM  Sucampo tops 4Q revenue forecasts
06:36AM  SUCAMPO PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors
06:30AM  Sucampo Reports Fourth Quarter and Full Year 2016 Financial Results GlobeNewswire
Feb-23-17 04:02PM  Sucampo Announces Fourth Quarter and Full Year 2016 Earnings Call GlobeNewswire
Feb-17-17 05:41PM  Sucampo Pharmaceuticals Set to Join S&P SmallCap 600 PR Newswire
02:04PM  Shire (SHPG) Beats on Q4 Earnings, Sales; Gives Upbeat View
Feb-16-17 04:25PM  Zoetis (ZTS) Beats Q4 Earnings Estimates, Lowers Outlook
Feb-09-17 10:36AM  Glaxo (GSK) Beats on Q4 Earnings, Posts Dismal '17 View
06:30AM  Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 2017 Leerink Global Healthcare Conference GlobeNewswire
Feb-07-17 10:56AM  Mallinckrodt (MNK) Tops on Earnings in Transition Quarter
Feb-06-17 08:19AM  Portola, HealthCare Royalty Partners Ink $150 Million Deal
Feb-03-17 08:06AM  AMAG Down Despite Positive Data on Makena Auto-Injector
Feb-02-17 09:49AM  Novartis (NVS) Votubia Gets EU Approval for Label Expansion
07:21AM  Catabasis Hits 52-Week Low on Poor DMD Drug Study Data
Jan-31-17 10:45AM  Mylan (MYL) Gets Favorable Verdict for Copaxone in the US
Jan-30-17 04:19PM  Endo (ENDP) Restructures Branded Pharmaceutical Unit (revised)
10:20AM  Celgene (CELG) Gets Favorable CHMP Opinion for Revlimid
Jan-27-17 02:42PM  AbbVie (ABBV) Q4 Earnings Meet Estimates, Revenues Lag
09:05AM  Endo (ENDP) Restructures its Branded Pharmaceutical Unit
Jan-26-17 03:29PM  Celgene (CELG) Misses on Earnings & Revenues, Keeps View
Jan-23-17 05:26PM  Gilead (GILD) HCV Therapy Application Validated in Europe
05:22PM  Bristol-Myers Settles Litigation with Merck for Keytruda
08:28AM  Prima Biomed Initiates Randomized Study for Breast Cancer
Jan-19-17 09:04AM  Apricus (APRI) Stock Gains on Vitaros' Approval in Mexico
Jan-18-17 08:29AM  Agenus, NCI Ink Deal to Evaluate Prophage-Keytruda Combo
08:26AM  Benitec Stock Up on Orphan Drug Status for BB-301 in EU
Jan-17-17 09:30AM featured highlights: Glaukos, Daqo New Energy, Calavo Growers and Sucampo Pharmaceuticals -5.60%
08:28AM  Key FDA Events to Watch Out for in Q1
Jan-16-17 08:16AM  4 Profitable Stocks with Amazingly High Returns
08:09AM  5 Top Ranked Stocks with Upgraded Broker Ratings to Buy Now
Jan-13-17 09:55AM  Coherus Offers Positive Phase III Data on Humira Biosimilar
Jan-12-17 04:19PM  TherapeuticsMD's Rejoice Study Data Published in Journal
08:43AM  Merck KGaA, Vertex Announce Tie-Up for Oncology Programs
Jan-11-17 04:42PM  Valeant Streamlines Portfolio with Skincare Brands Sale
09:30AM  The Zacks Analyst Blog Highlights: Sucampo Pharmaceuticals, Insulet, Western Refining, PennyMac Mortgage Investment Trust and Extended Stay America
08:27AM  Novo Nordisk (NVO) Fiasp Gets EU Nod for Diabetes in Adults
Jan-10-17 06:03PM  5 Underperformers of 2016: Turnaround Story in 2017?
09:30AM featured highlights: NVIDIA, Sucampo Pharmaceuticals, Calavo Growers, Tucows and E*TRADE Financial
Jan-09-17 08:23AM  Go Driehaus Way: 5 Momentum Picks
07:32AM  SUCAMPO PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Jan-06-17 10:18AM  Top Ranked Growth Stocks to Buy for January 6th
Jan-04-17 09:30AM  The Zacks Analyst Blog Highlights: Sucampo Pharmaceuticals, Dr. Reddy's Laboratories, BioMarin Pharmaceutical and Repligen
08:51AM  Why Sucampo Pharmaceuticals (SCMP)Could Be an Impressive Growth Stock
Jan-03-17 08:32AM  3 Overlooked Drug Stocks to Watch Out for in 2017
Dec-29-16 09:30AM featured highlights: Calavo Growers, Cytokinetics, Sucampo Pharmaceuticals, State National and CryoLife
Dec-28-16 07:37AM  5 Profitable Stocks to Buy for Great Returns
Dec-27-16 04:17PM  SUCAMPO PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Fi
09:07AM  Portola Betrixaban Accepted for Review in U.S. & EU, Stock Up
07:11AM  4 Top Stocks with Earnings Acceleration to Buy in 2017
Dec-23-16 11:22AM  Trump, Interest Rates And Biotech Investing In 2017 at Forbes
08:35AM  Ironwood, Allergan Report Positive Linzess IBS-C Study Data
Dec-22-16 01:19PM  Sucampo Pharmaceuticals, Inc. (SCMP) Announces Its New Debt Offering Of Convertible Notes at Insider Monkey
09:43AM  Sucampo Pharmaceuticals, Inc. Value Analysis (NASDAQ:SCMP) : December 22, 2016
06:14AM  Sucampo Pharma upgraded by Mizuho
Dec-21-16 04:15PM  Stock Indexes Calm; Southwestern Energy Up 6%
07:32AM  Sucampo Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : SCMP-US : December 21, 2016
02:00AM  Sucampo Announces Pricing of $260.0 Million 3.25% Convertible Senior Notes due 2021 GlobeNewswire
Dec-20-16 05:40PM  Why NeoPhotonics, Sucampo Pharmaceuticals, and Worthington Industries Slumped Today at Motley Fool -20.48%
02:50PM  Here's Why Sucampo Pharmaceuticals Is Down Over 20% Today at Motley Fool
01:36PM  Dow Flirts With 20,000 As Caterpillar, Goldman Sachs, Nike Score Gains
Dec-19-16 04:06PM  SUCAMPO PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits +6.03%
04:01PM  Sucampo Announces Proposed Convertible Senior Note Offering GlobeNewswire
01:47PM  Big-Cap Tech Names, Biotechs, Oils Lifting Market
08:47AM  Agios Stops Development of PKR Activator AG-519, Stock Falls
Dec-16-16 08:17AM  Roche (RHHBY) to Terminate Pacifica Bioscience Agreement
Dec-15-16 06:27AM  athenahealth (ATHN) Reaffirms 2016 View, Guides for 2017
Dec-14-16 09:17AM  Envision Healthcare Acquires Desert Mountain Consultants
08:09AM  Eli Lilly (LLY) to Offer Discount on Insulin from January
07:58AM  Kite Pharma Enters into Partnership with Vitruvian Networks
07:39AM  Proteon Slips to 52-Week Low on Kidney Disease Study Data
Dec-13-16 02:04PM  Top 10 Stocks Under $20
11:10AM  Stocks Stay Higher Ahead Of Fed; Dow Starts Eyeing 20,000
Dec-08-16 10:08AM  Pfizer (PFE) Fined for Price Hike of Anti-Epilepsy Drug in UK
09:30AM featured highlights: Lancaster Colony, Sucampo Pharmaceuticals, Citrix Systems, VMware and Sanchez Energy
09:00AM  Mylan (MYL) Stock Falls on Restructuring Plans, Layoffs
Dec-07-16 10:01AM  5 Stocks to Buy for Remarkable Earnings Growth in 2017 -5.51%
09:30AM  The Zacks Analyst Blog Highlights: Health Insurance Innovations, Aegean Marine Petroleum Network, KVH Industries, Sucampo Pharmaceuticals and Willdan Group
09:07AM  Sage Therapeutics Stock Up on SAGE-547 Regulatory Update
09:00AM  Novartis (NVS) Zykadia Positive in Phase III ASCEND-4 Study
08:55AM  Theravance Stock Up on Fast Track Status for Velusetrag
Dec-06-16 10:21AM  5 Best Small-Cap Stocks for 2017
08:24AM  GW Pharma (GWPH) Posts Narrower-than-Expected Q4 Loss
Dec-05-16 03:21PM  Is Sucampo Pharmaceuticals, Inc. (SCMP) A Good Stock To Buy? at Insider Monkey
Dec-01-16 10:23AM  Heat Biologics Stock Falls on Negative Bladder Cancer Data
08:25AM  Achaogen (AKAO) Catches Eye: Stock Adds 6.5% in Session
Nov-30-16 05:22PM  Cytori Scleroderma Study Two-Year Follow-Up Data Published -5.25%
09:53AM  PhaseRx Soars on Orphan Drug Status for Rare Liver Disease
Sucampo Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing, identifying, acquiring, and marketing medicines that meet unmet medical needs, primarily in gastroenterology, ophthalmology, and oncology-related disorders in the United States, Japan, Switzerland, and internationally. The company's marketed product includes AMITIZA (lubiprostone), a ClC-2 chloride channel activator for the treatment of chronic idiopathic constipation (CIC) in adults, irritable bowel syndrome with constipation in adult women (IBS-C), opioid-induced constipation (OIC)in patients with chronic non-cancer pain, and chronic constipation; and RESCULA (unoprostone isopropyl), a big potassium channel activator for the treatment of glaucoma and ocular hypertension. Its product candidates in clinical development stage comprise Lubiprostone that is in Phase IV clinical trials for the treatment of irritable bowel syndrome with constipation in adult women; Phase III clinical trials for the treatment of pediatric functional constipation and (IBS-C); and completed Phase III clinical trials for the treatment of (CIC) in adults, IBS-C in adult women, and OIC in patients with chronic non-cancer pain, as well as CPP-1X/sulindac combination product, which has completed Phase III clinical trials for the treatment of familial adenomatous polyposis. Sucampo Pharmaceuticals, Inc. was founded in 1996 is headquartered in Rockville, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Getman Daniel PDirectorNov 29Option Exercise6.803,79925,8333,799Nov 30 04:01 PM
Greenleaf PeterCEONov 29Option Exercise6.7582,459556,59884,972Nov 30 04:01 PM
Greenleaf PeterCEONov 29Sale16.7582,4591,381,1882,513Nov 30 04:01 PM
Getman Daniel PDirectorNov 29Sale16.753,79963,6330Nov 30 04:01 PM
Getman Daniel PDirectorNov 28Option Exercise6.8016,201110,16716,201Nov 30 04:01 PM
Greenleaf PeterCEONov 28Option Exercise6.75117,541793,402120,054Nov 30 04:01 PM
Alder MatthiasEVP, Bus. Dev.&Lic, G.C. &Sec.Nov 28Option Exercise8.3324,975208,04228,424Nov 28 09:30 PM
Alder MatthiasEVP, Bus. Dev.&Lic, G.C. &Sec.Nov 28Sale16.7324,975417,8323,449Nov 28 09:30 PM
Greenleaf PeterCEONov 28Sale16.91117,5411,987,6182,513Nov 30 04:01 PM
Getman Daniel PDirectorNov 28Sale16.8916,201273,6350Nov 30 04:01 PM
Alder MatthiasEVP, Bus. Dev.&Lic, G.C. &Sec.Nov 25Option Exercise8.3399,025824,878102,474Nov 28 09:30 PM
Alder MatthiasEVP, Bus. Dev.&Lic, G.C. &Sec.Nov 25Sale15.8899,0251,572,5173,449Nov 28 09:30 PM
Alder MatthiasEVP, Bus. Dev.&Lic, G.C. &Sec.Nov 23Option Exercise8.3326,000216,58029,449Nov 28 09:30 PM
Alder MatthiasEVP, Bus. Dev.&Lic, G.C. &Sec.Nov 23Sale15.7726,000410,0203,449Nov 28 09:30 PM
Smith Andrew PChief Financial OfficerNov 15Sale15.581,76627,514348Nov 16 04:01 PM